Michael Nedelcovych's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership • Q1 2025
Question
Michael Nedelcovych of Cowen asked about the competitive positioning of Takeda's TYK2 inhibitor, TAK-279, in IBD following a competitor's trial failure. He also inquired whether the reiteration of full-year guidance was overly cautious, given the better-than-expected performance of VYVANSE and other key products.
Answer
Andrew Plump, President of R&D, suggested the competitor's data was actually encouraging for TAK-279, noting Takeda is using higher, more optimal doses, and expressed continued confidence in its potential. CFO Milano Furuta explained that guidance was maintained because VYVANSE erosion is expected to accelerate and R&D spending is weighted towards the latter half of the year.